European Journal of Clinical Pharmacology

, Volume 62, Issue 4, pp 259–265

Effects of atorvastatin on higher functions

  • G. P. Parale
  • N. N. Baheti
  • P. M. Kulkarni
  • N. V. Panchal
Clinical Trials

Abstract

Objective

This study was undertaken to assess the effects of atorvastatin on cognition and higher mental functions.

Methods

In this before and after comparison study with controls, group one included 55 subjects aged ≥40 years requiring statins for cardiovascular indications who were started on atorvastatin (10 mg/day). Group two assigned to receive placebo were men and women chosen from the same geographical area and matched for age, sex, education and presence of hypertension and diabetes mellitus. Assessment was done with the Mini-Mental State Examination, Digit Span, Picture Test (average and delayed), Trail Making Test, Controlled Oral Word Association Test, Digit Symbol Substitution Test and Auditory Vigilance and Digit Vigilance Test at baseline and after 6 months. Changes between baseline and 6 months in the above parameters of mental function were compared using suitable statistical tests in the atorvastatin and placebo groups. To limit experiment-wise error, performance scores were grouped into five cognitive domains, which were labeled as attention, psychomotor speed, mental flexibility, working memory and memory retrieval. Summary effect sizes were estimated as z-scores.

Results

Both subjects on atorvastatin and placebo showed improvement in the majority of scales consistent with a learning effect on test performance. However, subjects treated with atorvastatin scored significantly over the placebo group in all domains, i.e. tests of attention [z-score=0.54, 95% confidence interval (CI): 0.38–0.64, p=0.001], psychomotor speed (z-score=0.28, 95% CI: O.09–0.47, p<0.001), mental flexibility (z-score=0.27, 95% CI: 0.22–0.32, p=0.01), working memory (z-score=1.22, 95% CI: 0.93–1.50, p<0.001) and memory retrieval (z-score=0.59, 95% CI: 0.36–0.82, p<0.05).

Conclusion

The present study concludes that there are significant beneficial effects of atorvastatin in a dose of 10 mg/day for a period of 6 months on higher functions as measured by the above standard neurocognitive tests.

Keywords

Statins Neurocognitive tests Atorvastatin Memory MMSE 

References

  1. 1.
    Beatrice A, Golomb MH (2004) Conceptual foundations of UCSD Statin Study. Arch Int Med 164:153–162CrossRefGoogle Scholar
  2. 2.
    Benton D (1995) Do cholesterol levels slow mental processing? Psychosom Med 57:50–53PubMedGoogle Scholar
  3. 3.
    Cattin L, Bordin P, Fonda M et al (1997) Factors associated with cognitive impairment among older Italian inpatients. J Am Geriatr Soc 45:1324–1330PubMedGoogle Scholar
  4. 4.
    Cutler N, Sramek J, Veroff A, Block G, Stauffer L, Lines C (1995) Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolemia. Br J Clin Pharmacol 39:333–336PubMedGoogle Scholar
  5. 5.
    Davidson MH (2001) Safety profiles for the HMG Co-A reductase inhibitors: treatment and trust. Drugs 61:197–206CrossRefPubMedGoogle Scholar
  6. 6.
    Dales MJM (2000) Statination. Intern Med News 1:55–56Google Scholar
  7. 7.
    Dietschy JM, Turley SD (2001) Cholesterol metabolism in the brain. Curr Opin Lipidol 12:105–112CrossRefPubMedGoogle Scholar
  8. 8.
    England JD, Viles A, Walsh JC, Stewart PM (1999) Muscle side effects associated with simvastatin therapy. Med J Aust 153:562–563Google Scholar
  9. 9.
    Fassbender K, Simons M, Bergmann C, Stroick M et al (2001) Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98:5856–5861PubMedCrossRefGoogle Scholar
  10. 10.
    Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMedGoogle Scholar
  11. 11.
    Friedewald WT, Levy RI, Friedrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18(6)499–502PubMedGoogle Scholar
  12. 12.
    Golomb BA (1998) Cholesterol and violence: is there a connection? Ann Intern Med 128:478–487PubMedGoogle Scholar
  13. 13.
    Grobbee ED, Bots LM (2003) Statin treatment and progression of atherosclerotic plaque burden. Drugs 63(9):893–911CrossRefPubMedGoogle Scholar
  14. 14.
    Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP (2002) The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 57(7):M414–M418PubMedGoogle Scholar
  15. 15.
    Harrison RWS, Ashton CH (1994) Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol 37(3):231–236PubMedGoogle Scholar
  16. 16.
    Houx PJ, Shepherd J, Blauw GJ et al (2002) Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Psychiatry 73(4):385–389CrossRefPubMedGoogle Scholar
  17. 17.
    Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356(9242):1627–1631CrossRefPubMedGoogle Scholar
  18. 18.
    King DS, Wilburn AJ, Wofford MR et al (2003) Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 23(12):1663–1667CrossRefPubMedGoogle Scholar
  19. 19.
    Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM10. Proc Natl Acad Sci USA 98:5815–5820PubMedCrossRefGoogle Scholar
  20. 20.
    Krysiak R, Okopie B, Herman SZ (2003) Statin treatment and progression of atherosclerotic plaque burden. Drugs 63(9):893–911CrossRefPubMedGoogle Scholar
  21. 21.
    Laufs U, Bohm M, Gertz K et al (2002) The hydrophilic HMG-CoA reductase inhibitor rosuvastatin regulates endothelial NO synthase and ischaemic stroke in vivo. Circulation 106(19 suppl):I272Google Scholar
  22. 22.
    Lewis RF, Rennick PM (1979) Manual for repeatable cognitive perceptual motor battery. Axon, Clinton, MIGoogle Scholar
  23. 23.
    Mason RP, Herbette LG, Silverman DI (1991) Can altering serum cholesterol affect neurologic functions? J Mol Cell Cardiol 23:1339–1342CrossRefPubMedGoogle Scholar
  24. 24.
    Muldoon MF, Barger SD, Ryan CM et al (2000) Effects of lovastatin on cognitive function and psychological well-being. Am J Med 108:538–546CrossRefPubMedGoogle Scholar
  25. 25.
    Muldoon MF, Flory JD, Ryan CM (2000) Serum cholesterol, the brain and cognitive functioning. In: Waldstein SR, Elias MF (eds) Neuropsychology of cardiovascular disease. Lawrence Erlbaum Associates, Mahwah, NJGoogle Scholar
  26. 26.
    Nangle MR, Cotter MA, Cameron NE (2003) Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpora cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. Diabetes 52(9):2396–2402PubMedCrossRefGoogle Scholar
  27. 27.
    Orsi A, Sherman O, Woldeselassie Z (2001) Simvastatin-associated memory loss. Pharmacotherapy 21(6):767–769CrossRefPubMedGoogle Scholar
  28. 28.
    Raggat JL, Partridge CN (2002) HMG CoA reductase inhibitors as immunomodulators: potential use in transplant rejection. Drugs 62(15):2185–2191CrossRefPubMedGoogle Scholar
  29. 29.
    Reitan RM, Wolfson D (1993) The Halstead-Reitan neuropsychological test battery. Theory and clinical interpretation, 2nd edn. Neuropsychological Press, Tucson AZGoogle Scholar
  30. 30.
    Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly. Arch Neurol 59(2):223–227CrossRefPubMedGoogle Scholar
  31. 31.
    Rose GA, Blackburn H, Gillum RF, Prineas RJ (1982) Cardiovascular survey methods, 2nd edn. (WHO Monograph Series no. 56 vol 1) WHO, GenevaGoogle Scholar
  32. 32.
    Waldstein SR, Jennings, JR, Ryan CM et al (1996) Hypertension and neuropsychological performance in man: interactive effects of age. Health Psychol 15:102–109CrossRefPubMedGoogle Scholar
  33. 33.
    Ryman A (1994) Cholesterol, violent death and mental disorder. BMJ 309:421–422PubMedGoogle Scholar
  34. 34.
    Shepherd J, Blauw GJ, Murphy MB et al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623–1630CrossRefPubMedGoogle Scholar
  35. 35.
    Simons M, Schwarzler F, Lutjohann D et al (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52:346–350CrossRefPubMedGoogle Scholar
  36. 36.
    Sparks DL, Connor DJ, Browne PJ et al (2002) HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer’s disease and why it would be ill-advised to use one that crosses the blood-brain barrier. J Nutr Health Aging 6:323–324Google Scholar
  37. 37.
    Spreen O, Strauss E (1991) A compendium of neuropsychological tests. Administration, norms, and commentary. Oxford University Press, New YorkGoogle Scholar
  38. 38.
    Stalker TJ, Lefer AM, Scalia R (2001) A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvasculature endothelium: the role of mevalonic acid. Br J Pharmacol 133(3):406–412CrossRefPubMedGoogle Scholar
  39. 39.
    Wagstaff LR, Mitton MW, Arvik BM et al (2003) Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 23(7):871–880CrossRefPubMedGoogle Scholar
  40. 40.
    Wechsler D (1997) Wechsler Adult Intelligence Scale, 3rd edn. Psychological Corporation, San Antonio, TXGoogle Scholar
  41. 41.
    Wehr H, Parnowski T, Puzynski S et al (1996) Apolipoprotein E genotype and lipid and lipoprotein levels in dementia. Age Ageing 15:267–270Google Scholar
  42. 42.
    Wolozin B, Kellman W, Rousseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3–hydroxy–3–methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439–1443CrossRefPubMedGoogle Scholar
  43. 43.
    Yaffe K, Barrett–Connor E, Lin F, Grady D (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59(3):378–384CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • G. P. Parale
    • 1
  • N. N. Baheti
    • 1
  • P. M. Kulkarni
    • 1
  • N. V. Panchal
    • 2
  1. 1.Department of MedicineDr. V.M. Medical College SolapurMaharashtraIndia
  2. 2.Clinical PharmacistSpandan Cardiac Diagnostic Centre, SolapurMaharashtraIndia

Personalised recommendations